Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX)
· seekingalpha.com
Forte Biosciences (FBRX) surged on 2026 FB102 data hopes. See here for Phase 1b celiac results, competition risks, valuation vs. cash, and outlook.
Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a m...